Drugs / SDN-037
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03426267 | Sep 2018 → Mar 2020 | — | Sun Pharma Advanced Research Company Limited | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-14 | Sun Pharma Advanced Research Company Limited | Results SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery Met Pre -specified Primary and Secondary Endpoint s sparc.life ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-08 | Sun Pharma Advanced Research Company Limited | SPARC Licenses Development and Commercialization Rights of PDP-716 and SDN-037 to Visiox Pharma SPARC out-licenses PDP-716 and SDN-037 SPARC to receive equity in Visiox along with other financial considerations sparc.life ↗ |
| 2020-10-14 | Sun Pharma Advanced Research Company Limited | SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of SDN-037 for the Treatment of Inflammation and Pain Associated with Ocular Surgery Met Pre -specified Primary and Secondary Endpoint s sparc.life ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SDN-037 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03426267 ↗ |